195522 Effects of fish oil supplementation on markers of cardiovascular disease

Sunday, November 8, 2009

Rodney G. Bowden, PhD , Hhpr, Baylor University, Waco, TX
Ronald L. Wilson, MD , Central Texas Nephrology Associates, Waco, TX
Erika Deike, MS , Human Peformance, Wayland Baptist University, Planview, TX
Mindy Gentile, MS, RD, LD , Brazos Kidney Center, Waco, TX
Introduction: Fish oil (FO) has been suggested as a nutritional approach to controlling lipid levels and cardiovascular disease. End-Stage Renal Disease (ESRD) patients have an accelerated cardiovascular disease risk profile when compared to apparently healthy populations. Therefore the purpose of this study was study the effects of FO supplementation on lipid markers in ESRD patients. Methods: The study was a double-blind, permuted-randomized, and placebo controlled experimental protocol. Patients were randomly placed into a FO or control group (corn oil). Thirty-four (N=34) patients in the experimental and control groups ingested two softgel pills (1 gram each) of FO supplements containing EPA and DHA or placebo at each meal. Patients followed the supplementation protocol for six months. ANOVA was used to measure pretest and posttest differences in total cholesterol, triglycerides, HDL, LDL, VLDL, LDL particle number, LDL size, large HDL, large VLDL, and Lp(a). Results: ANOVA revealed no statistically significant difference between groups at baseline for each variable. ANOVA reported a significant main effect (f=42.97, p=.007) for HDL and LDL (f=14.33, p=.032) with the FO group having lower values at posttest when compared to the placebo. Conclusions: ESRD patients have elevated lipid values and novel approaches to controlling these levels are warranted. Our study suggests that FO supplementation may lead to changes in HDL and LDL suggesting its use may be helpful in reducing cardiovascular disease. More study is needed to understand why other lipid markers were not significantly different.

Learning Objectives:
1. Participants will learn about disease progression with End-Stage Renal Disease 2. Participants will learn about fish oil supplementation and its effects on cardiovascular disease 3. Participants will learn about accelerated risk profiles of ESRD patients

Keywords: Cholesterol, Chronic (CVD)

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am the PI for this study
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.